-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 22, the official website of NMPA showed that Simcere's bortezomib for injection passed the consistency evaluation of generic drugs
.
Bortezomib is a new type of targeted anticancer drug, and its terminal sales in China's public medical institutions will exceed 1.
7 billion yuan in 2020
.
.
Bortezomib is a new type of targeted anticancer drug, and its terminal sales in China's public medical institutions will exceed 1.
7 billion yuan in 2020
.
Bortezomib is a proteasome inhibitor.
It is a new type of anticancer drug for targeted therapy.
It is mainly used to treat multiple myeloma and mantle cell lymphoma.
It has fast onset and high safety (can be used for renal insufficiency Even patients with renal failure)
.
It is a new type of anticancer drug for targeted therapy.
It is mainly used to treat multiple myeloma and mantle cell lymphoma.
It has fast onset and high safety (can be used for renal insufficiency Even patients with renal failure)
.
According to data from Menet.
com, in 2020, the sales of bortezomib in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 1.
7 billion yuan, a year-on-year increase of 20.
22%
.
Among them, Xi'an Janssen accounted for 45.
59% of the market share, and Hausen accounted for 22.
95%
.
com, in 2020, the sales of bortezomib in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 1.
7 billion yuan, a year-on-year increase of 20.
22%
.
Among them, Xi'an Janssen accounted for 45.
59% of the market share, and Hausen accounted for 22.
95%
.
Sales of terminal bortezomib in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
With the injection of boron Simcere bortezomib through assessment, the current assessment of the product through the enterprise has reached eight, including CTTQ, Yangtze River Pharmaceutical, Shijiazhuang Pharmaceutical Group, Qilu Pharmaceutical, medicine, and other Stockhausen
.
In addition, the bortezomib for injection of 3 companies including Huiyu Pharmaceutical, Tasly, Renhe Xidelong Pharmaceutical, etc.
is under review for the imitation of 4 types of production
.
.
In addition, the bortezomib for injection of 3 companies including Huiyu Pharmaceutical, Tasly, Renhe Xidelong Pharmaceutical, etc.
is under review for the imitation of 4 types of production
.
Up to now, been Simcere 16 cultivars / deemed by evaluation consistency, wherein the anti- cancer drugs are 5, including injection nedaplatin, Lun cutting imatinib mesylate capsules, injection pemetrexed Disodium plug, bendamustine hydrochloride for injection and bortezomib for injection
.
.
Data source: Mi Neiwang database, NMPA
On November 22, the official website of NMPA showed that Simcere's bortezomib for injection passed the consistency evaluation of generic drugs
.
Bortezomib is a new type of targeted anticancer drug, and its terminal sales in China's public medical institutions will exceed 1.
7 billion yuan in 2020
.
.
Bortezomib is a new type of targeted anticancer drug, and its terminal sales in China's public medical institutions will exceed 1.
7 billion yuan in 2020
.
Bortezomib is a proteasome inhibitor.
It is a new type of anticancer drug for targeted therapy.
It is mainly used to treat multiple myeloma and mantle cell lymphoma.
It has fast onset and high safety (can be used for renal insufficiency Even patients with renal failure)
.
It is a new type of anticancer drug for targeted therapy.
It is mainly used to treat multiple myeloma and mantle cell lymphoma.
It has fast onset and high safety (can be used for renal insufficiency Even patients with renal failure)
.
According to data from Menet.
com, in 2020, the sales of bortezomib in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 1.
7 billion yuan, a year-on-year increase of 20.
22%
.
Among them, Xi'an Janssen accounted for 45.
59% of the market share, and Hausen accounted for 22.
95%
.
com, in 2020, the sales of bortezomib in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 1.
7 billion yuan, a year-on-year increase of 20.
22%
.
Among them, Xi'an Janssen accounted for 45.
59% of the market share, and Hausen accounted for 22.
95%
.
Sales of terminal bortezomib in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
With the injection of boron Simcere bortezomib through assessment, the current assessment of the product through the enterprise has reached eight, including CTTQ, Yangtze River Pharmaceutical, Shijiazhuang Pharmaceutical Group, Qilu Pharmaceutical, medicine, and other Stockhausen
.
In addition, the bortezomib for injection of 3 companies including Huiyu Pharmaceutical, Tasly, Renhe Xidelong Pharmaceutical, etc.
is under review for the imitation of 4 types of production
.
.
In addition, the bortezomib for injection of 3 companies including Huiyu Pharmaceutical, Tasly, Renhe Xidelong Pharmaceutical, etc.
is under review for the imitation of 4 types of production
.
Up to now, been Simcere 16 cultivars / deemed by evaluation consistency, wherein the anti- cancer drugs are 5, including injection nedaplatin, Lun cutting imatinib mesylate capsules, injection pemetrexed Disodium plug, bendamustine hydrochloride for injection and bortezomib for injection
.
.
Data source: Mi Neiwang database, NMPA
On November 22, the official website of NMPA showed that Simcere's bortezomib for injection passed the consistency evaluation of generic drugs
.
Bortezomib is a new type of targeted anticancer drug, and its terminal sales in China's public medical institutions will exceed 1.
7 billion yuan in 2020
.
.
Bortezomib is a new type of targeted anticancer drug, and its terminal sales in China's public medical institutions will exceed 1.
7 billion yuan in 2020
.
Bortezomib is a proteasome inhibitor.
It is a new type of anticancer drug for targeted therapy.
It is mainly used to treat multiple myeloma and mantle cell lymphoma.
It has fast onset and high safety (can be used for renal insufficiency Even patients with renal failure)
.
It is a new type of anticancer drug for targeted therapy.
It is mainly used to treat multiple myeloma and mantle cell lymphoma.
It has fast onset and high safety (can be used for renal insufficiency Even patients with renal failure)
.
According to data from Menet.
com, in 2020, the sales of bortezomib in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 1.
7 billion yuan, a year-on-year increase of 20.
22%
.
Among them, Xi'an Janssen accounted for 45.
59% of the market share, and Hausen accounted for 22.
95%
.
Hospital hospital hospitalcom, in 2020, the sales of bortezomib in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 1.
7 billion yuan, a year-on-year increase of 20.
22%
.
Among them, Xi'an Janssen accounted for 45.
59% of the market share, and Hausen accounted for 22.
95%
.
Sales of terminal bortezomib in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
With the injection of boron Simcere bortezomib through assessment, the current assessment of the product through the enterprise has reached eight, including CTTQ, Yangtze River Pharmaceutical, Shijiazhuang Pharmaceutical Group, Qilu Pharmaceutical, medicine, and other Stockhausen
.
In addition, the bortezomib for injection of 3 companies including Huiyu Pharmaceutical, Tasly, Renhe Xidelong Pharmaceutical, etc.
is under review for the imitation of 4 types of production
.
Enterprise business enterprise.
In addition, the bortezomib for injection of 3 companies including Huiyu Pharmaceutical, Tasly, Renhe Xidelong Pharmaceutical, etc.
is under review for the imitation of 4 types of production
.
Up to now, been Simcere 16 cultivars / deemed by evaluation consistency, wherein the anti- cancer drugs are 5, including injection nedaplatin, Lun cutting imatinib mesylate capsules, injection pemetrexed Disodium plug, bendamustine hydrochloride for injection and bortezomib for injection
.
Tumor tumor tumor.
Data source: Mi Neiwang database, NMPA
